Free Trial
NYSE:BDX

Becton, Dickinson and Company Q3 2025 Earnings Report

Becton, Dickinson and Company logo
$177.36 +1.86 (+1.06%)
Closing price 03:59 PM Eastern
Extended Trading
$177.52 +0.15 (+0.09%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company EPS Results

Actual EPS
N/A
Consensus EPS
$3.44
Beat/Miss
N/A
One Year Ago EPS
N/A

Becton, Dickinson and Company Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.50 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Becton, Dickinson and Company Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Becton, Dickinson and Company Earnings Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More Becton, Dickinson and Company Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Becton, Dickinson and Company? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Becton, Dickinson and Company and other key companies, straight to your email.

About Becton, Dickinson and Company

Becton, Dickinson and Company (NYSE:BDX), commonly known as BD, is a leading global medical technology firm founded in 1897 by Maxwell Becton and Fairleigh Dickinson. Headquartered in Franklin Lakes, New Jersey, BD has evolved from a regional syringe manufacturer into a diversified supplier of medical devices, instrument systems and reagents. Over more than a century, the company has gained a reputation for quality and innovation, serving hospitals, clinical laboratories, life science researchers and pharmaceutical organizations worldwide.

BD’s operations are organized into three primary segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment delivers needles and syringes, infusion therapy and injection safety solutions designed to enhance patient comfort and reduce needlestick injuries. BD Life Sciences offers advanced diagnostic and research tools, including flow cytometry, molecular testing, microbiology systems and cellular analysis products. BD Interventional, strengthened by the 2017 acquisition of C.R. Bard, focuses on vascular access, oncology and surgical devices such as catheters, biopsy systems and drainage solutions.

With a presence in over 190 countries, BD operates manufacturing, distribution and research facilities across North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. This expansive footprint enables the company to collaborate closely with healthcare providers and researchers, addressing regional challenges like infection prevention, chronic disease management and the rise of personalized medicine. BD’s global supply chain emphasizes rigorous quality assurance and regulatory compliance to ensure reliable product availability.

Under the leadership of President and Chief Executive Officer Thomas Polen, who assumed the role in February 2020, BD continues to invest significantly in research and development. Supported by an experienced executive team and board of directors, the company pursues innovations in digital health, advanced diagnostics and minimally invasive therapies. Through strategic partnerships, targeted acquisitions and internal development, BD aims to drive sustainable growth while advancing healthcare delivery and patient safety around the globe.

View Becton, Dickinson and Company Profile

More Earnings Resources from MarketBeat